201 related articles for article (PubMed ID: 22158723)
21. Targeted chemotherapy of visceral leishmaniasis by lactoferrin-appended amphotericin B-loaded nanoreservoir: in vitro and in vivo studies.
Asthana S; Gupta PK; Jaiswal AK; Dube A; Chourasia MK
Nanomedicine (Lond); 2015; 10(7):1093-109. PubMed ID: 25929567
[TBL] [Abstract][Full Text] [Related]
22. Amphotericin B: A drug of choice for Visceral Leishmaniasis.
Kumari S; Kumar V; Tiwari RK; Ravidas V; Pandey K; Kumar A
Acta Trop; 2022 Nov; 235():106661. PubMed ID: 35998680
[TBL] [Abstract][Full Text] [Related]
23. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys.
Berman JD; Hanson WL; Chapman WL; Alving CR; Lopez-Berestein G
Antimicrob Agents Chemother; 1986 Dec; 30(6):847-51. PubMed ID: 3813512
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.
Corral MJ; Serrano DR; Moreno I; Torrado JJ; Domínguez M; Alunda JM
J Antimicrob Chemother; 2014 Dec; 69(12):3268-74. PubMed ID: 25096077
[TBL] [Abstract][Full Text] [Related]
25. Study the effects of PLGA-PEG encapsulated amphotericin B nanoparticle drug delivery system against Leishmania donovani.
Kumar R; Sahoo GC; Pandey K; Das V; Das P
Drug Deliv; 2015 May; 22(3):383-8. PubMed ID: 24601828
[TBL] [Abstract][Full Text] [Related]
26. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses.
Banerjee A; De M; Ali N
J Immunol; 2008 Jul; 181(2):1386-98. PubMed ID: 18606693
[TBL] [Abstract][Full Text] [Related]
27. Antileishmanial activity of nano-amphotericin B deoxycholate.
Manandhar KD; Yadav TP; Prajapati VK; Kumar S; Rai M; Dube A; Srivastava ON; Sundar S
J Antimicrob Chemother; 2008 Aug; 62(2):376-80. PubMed ID: 18453526
[TBL] [Abstract][Full Text] [Related]
28. Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome
Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Alavijeh M; Silva-Pedrosa R; Antunes S; Mauricio I; Murdan S; Croft SL
Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):223-228. PubMed ID: 29673889
[TBL] [Abstract][Full Text] [Related]
29. Nanonization increases the antileishmanial efficacy of amphotericin B: an ex vivo approach.
Manandhar KD; Yadav TP; Prajapati VK; Basukala O; Aganja RP; Dude A; Shrivastav ON; Sundar S
Adv Exp Med Biol; 2014; 808():77-91. PubMed ID: 24595612
[TBL] [Abstract][Full Text] [Related]
30. A new nanoemulsion formulation improves antileishmanial activity and reduces toxicity of amphotericin B.
Santos DCMD; de Souza MLS; Teixeira EM; Alves LL; Vilela JMC; Andrade M; Carvalho MDG; Fernandes AP; Ferreira LAM; Aguiar MMG
J Drug Target; 2018 Apr; 26(4):357-364. PubMed ID: 29041824
[TBL] [Abstract][Full Text] [Related]
31. Study of parasite kinetics with antileishmanial drugs using real-time quantitative PCR in Indian visceral leishmaniasis.
Sudarshan M; Weirather JL; Wilson ME; Sundar S
J Antimicrob Chemother; 2011 Aug; 66(8):1751-5. PubMed ID: 21609983
[TBL] [Abstract][Full Text] [Related]
32. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.
Gangneux JP; Sulahian A; Garin YJ; Derouin F
Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278
[TBL] [Abstract][Full Text] [Related]
33. A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model.
Wasan EK; Gershkovich P; Zhao J; Zhu X; Werbovetz K; Tidwell RR; Clement JG; Thornton SJ; Wasan KM
PLoS Negl Trop Dis; 2010 Dec; 4(12):e913. PubMed ID: 21151883
[TBL] [Abstract][Full Text] [Related]
34. ABLE: a new and improved amphotericin B for visceral leishmaniasis?
Berman J
Am J Trop Med Hyg; 2009 May; 80(5):689-90. PubMed ID: 19407106
[No Abstract] [Full Text] [Related]
35. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
[TBL] [Abstract][Full Text] [Related]
36. Amphotericin B molecular organization as an essential factor to improve activity/toxicity ratio in the treatment of visceral leishmaniasis.
Sánchez-Brunete JA; Dea MA; Rama S; Bolás F; Alunda JM; Torrado-Santiago S; Torrado JJ
J Drug Target; 2004; 12(7):453-60. PubMed ID: 15621670
[TBL] [Abstract][Full Text] [Related]
37. Liposomal amphotericin B in drug-resistant visceral leishmaniasis.
Davidson RN; Croft SL; Scott A; Maini M; Moody AH; Bryceson AD
Lancet; 1991 May; 337(8749):1061-2. PubMed ID: 1673494
[TBL] [Abstract][Full Text] [Related]
38. Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters.
Agrawal AK; Agrawal A; Pal A; Guru PY; Gupta CM
J Drug Target; 2002 Feb; 10(1):41-5. PubMed ID: 11996085
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis.
Mullen AB; Carter KC; Baillie AJ
Antimicrob Agents Chemother; 1997 Oct; 41(10):2089-92. PubMed ID: 9333030
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics, biodistribution, and activity of Amphotericin B-loaded nanocochleates on the Leishmania donovani murine visceral leishmaniasis model.
Lipa Castro A; Pomel S; Cailleau C; Fournier N; Dennemont I; Loiseau PM; Barratt G
Int J Pharm; 2022 Aug; 624():121985. PubMed ID: 35820519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
